https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-at-conferences-during-january-2022-2022-01-05
https://www.nasdaq.com/press-release/autolus-therapeutics-presents-positive-obe-cel-data-at-the-63rd-ash-annual-meeting
https://www.nasdaq.com/press-release/autolus-therapeutics-announce-new-time-for-investor-call-to-discuss-data-presented-at
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-the-appointment-of-dr.-william-d.-young-as-a-non
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-publication-describing-its-small-molecule-regulated
https://www.nasdaq.com/press-release/blackstone-life-sciences-to-invest-up-to-%24250-million-in-autolus-therapeutics-to
https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-new-data-at-the-63rd-ash-annual-meeting-exposition
https://www.nasdaq.com/press-release/autolus-therapeutics-reports-third-quarter-2021-financial-results-and-operational
https://www.nasdaq.com/press-release/autolus-therapeutics-to-report-third-quarter-2021-financial-results-and-host
https://www.nasdaq.com/press-release/gain-therapeutics-appoints-matthias-alder-as-chief-operating-officer-2021-10-19
https://www.nasdaq.com/press-release/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-the-appointment-of-john-h.-johnson-as-non-executive
https://www.nasdaq.com/press-release/autolus-therapeutics-to-participate-in-upcoming-virtual-investor-conferences-2021-09
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-publication-of-obe-cel-auto1-phase-1-allcar19-data-in
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-promising-innovative-medicine-pim-designation-for-obe
https://www.nasdaq.com/press-release/autolus-therapeutics-reports-second-quarter-2021-financial-results-and-operational
https://www.nasdaq.com/press-release/autolus-and-moderna-sign-option-and-license-agreement-for-access-to-proprietary
https://www.nasdaq.com/press-release/autolus-announces-appointment-of-edgar-braendle-m.d.-ph.d.-as-chief-development
https://www.nasdaq.com/press-release/autolus-therapeutics-to-report-second-quarter-2021-financial-results-on-august-5-2021
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-innovation-licensing-and-access-pathway-ilap
https://www.nasdaq.com/press-release/autolus-therapeutics-presents-new-data-on-obe-cel-in-r-r-indolent-b-cell-lymphomas
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-an-additional-nature-publication-for-auto1-2021-05-25
https://www.nasdaq.com/press-release/autolus-notice-of-annual-general-meeting-agm-on-friday-june-18-2021-2021-05-21
https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-new-data-on-auto1-in-r-r-indolent-b-cell-lymphomas-at
https://www.nasdaq.com/press-release/autolus-therapeutics-reports-first-quarter-2021-financial-results-and-operational
https://www.nasdaq.com/press-release/autolus-therapeutics-to-report-first-quarter-2021-financial-results-and-host
https://www.nasdaq.com/press-release/autolus-therapeutics-receives-innovation-passport-and-entry-into-ilap-for-auto4-for
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-appointment-of-martin-murphy-as-non-executive-chairman
https://www.nasdaq.com/press-release/exact-therapeutics-as-announces-appointment-of-dominic-moreland-as-chief-financial
https://www.nasdaq.com/press-release/autolus-therapeutics-to-participate-in-investor-conferences-through-april-2021-04-01
https://www.nasdaq.com/press-release/autolus-therapeutics-receives-prime-designation-for-auto1-for-the-treatment-of-adult
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-updated-manufacturing-facility-strategy-leveraging-its
https://www.nasdaq.com/press-release/autolus-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-at-the-h.c.-wainwright-global-life-sciences
https://www.nasdaq.com/press-release/autolus-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase
https://www.nasdaq.com/press-release/autolus-announces-pricing-of-public-offering-2021-02-09
https://www.nasdaq.com/press-release/autolus-announces-proposed-public-offering-in-the-united-states-2021-02-08
https://www.nasdaq.com/press-release/autolus-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/autolus-therapeutics-provides-business-outlook-for-2021-2022-2021-01-06
https://www.nasdaq.com/press-release/autolus-therapeutics-to-participate-in-investor-conferences-through-january-2021-01
https://www.nasdaq.com/press-release/autolus-therapeutics-presents-additional-data-on-auto3-in-dlbcl-during-the-62nd-ash
https://www.nasdaq.com/press-release/autolus-therapeutics-presents-compelling-auto1-data-from-allcar-phase-1-study-in
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-publication-of-new-auto6-phase-1-data-in-childhood
https://www.nasdaq.com/press-release/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data
https://www.nasdaq.com/press-release/autolus-therapeutics-reports-third-quarter-2020-financial-results-and-operational
https://www.nasdaq.com/press-release/autolus-therapeutics-to-report-third-quarter-2020-financial-results-and-host
https://www.nasdaq.com/press-release/autolus-therapeutics-presents-additional-data-on-auto3-in-dlbcl-during-the-esmo
https://www.nasdaq.com/press-release/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto3-data-presented
https://www.nasdaq.com/press-release/autolus-therapeutics-reports-second-quarter-2020-financial-results-and-operational
https://www.nasdaq.com/press-release/autolus-announces-changes-to-its-board-and-management-team-2020-08-04
https://www.nasdaq.com/press-release/autolus-therapeutics-to-report-second-quarter-2020-financial-results-and-host
https://www.nasdaq.com/press-release/autolus-therapeutics-presents-new-preclinical-data-during-the-virtual-2020-aacr
https://www.nasdaq.com/press-release/autolus-therapeutics-presents-auto1-and-auto3-data-at-the-2020-eha25-virtual-congress
https://www.nasdaq.com/press-release/autolus-therapeutics-reschedules-its-investor-eha-conference-call-2020-06-08
https://www.nasdaq.com/press-release/autolus-therapeutics-presents-additional-data-on-auto3-in-dlbcl-during-the-asco20
https://www.nasdaq.com/press-release/autolus-therapeutics-to-host-investor-conference-calls-through-june-2020-05-26
https://www.nasdaq.com/press-release/autolus-notice-of-annual-general-meeting-agm-on-thursday-june-18-2020-2020-05-22
https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-new-data-at-the-virtual-2020-aacr-annual-meeting-2020
https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-new-data-on-auto1-and-auto3-at-the-2020-eha-annual
https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-new-data-on-auto3-during-the-asco20-virtual
https://www.nasdaq.com/press-release/autolus-therapeutics-reports-first-quarter-2020-financial-results-and-operational
https://www.nasdaq.com/press-release/autolus-therapeutics-to-report-first-quarter-2020-financial-results-and-host
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-fda-acceptance-of-ind-application-for-auto1-for-adult
https://www.nasdaq.com/press-release/autolus-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-at-the-cowen-40th-annual-health-care-conference-2020
https://www.nasdaq.com/press-release/autolus-therapeutics-to-report-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/autolus-therapeutics-presents-encouraging-additional-data-showcasing-clinical
https://www.nasdaq.com/press-release/autolus-announces-closing-of-public-offering-2020-01-27
https://www.nasdaq.com/press-release/autolus-chief-scientific-officer-dr-martin-pule-to-give-keynote-lecture-at-the-eha
https://www.nasdaq.com/press-release/autolus-announces-pricing-of-public-offering-2020-01-23
https://www.nasdaq.com/press-release/autolus-announces-proposed-public-offering-in-the-united-states-2020-01-22
https://www.nasdaq.com/press-release/autolus-therapeutics-to-provide-outlook-for-2020-at-the-38th-annual-j.p.-morgan
https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-at-the-38th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-new-data-showcasing-clinical-progress-of-auto3-in-b
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-new-data-showcasing-clinical-progress-of-programmed-t
https://www.nasdaq.com/press-release/autolus-therapeutics-announces-conference-call-to-review-clinical-data-for-programmed
https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-at-the-jefferies-2019-london-healthcare-conference
https://www.nasdaq.com/press-release/autolus-therapeutics-and-noile-immune-announce-licensing-agreement-2019-11-13
https://www.nasdaq.com/press-release/autolus-therapeutics-presents-preclinical-data-on-aut06ng-at-the-sitc-annual-meeting
https://www.nasdaq.com/press-release/autolus-therapeutics-reports-third-quarter-2019-financial-results-and-operational
https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-new-data-on-its-advanced-programmed-t-cell-therapies
https://www.nasdaq.com/press-release/autolus-therapeutics-to-present-preclinical-data-on-aut06ng-at-the-sitc-annual
https://www.nasdaq.com/press-release/autolus-therapeutics-receives-fda-orphan-drug-designation-for-auto1-for-treatment-of
https://www.nasdaq.com/press-release/autolus-therapeutics-to-report-third-quarter-2019-financial-results-and-host
